Correlation of serum prolactin level with multiple sclerosis

Koocheki, E. and Masoud, S.A. and Moosavi, G.A. (2006) Correlation of serum prolactin level with multiple sclerosis. Feyz Journal of Kashan University of Medical Sciences, 10.

Full text not available from this repository.
Official URL: http://feyz.kaums.ac.ir/article-1-94-en.html
DOI: UNSPECIFIED

Abstract

Background: Multiple Sclerosis (MS) is a chronic disease with unknown etiology producing inflammation and degeneration of brain white matter and characterized by the replacement of gliosis tissue. This disease is considered to be multifactorial with an autoimmune component. Prolactin (PRL) is a neuroendocrine peptide with potent immunomodulatory properties. Hyperprolactinemia enhances several autoimmune disorders and may play a role in the pathogenesis of MS. Considering controversies in correlation between serum prolactin level with multiple sclerosis, this study was done to compare serum PRL levels in MS patients with those in healthy persons referred to neurological centers of Kashan during 2004-2005. Materials & Methods: This is an analytical survey (Case control) evaluating the serum prolactin level in 35 patients with clinically definite Multiple Sclerosis and 35 healthy controls. Fasting blood sample was drawn and measured with ELISA Kits and RIA method and t test were used to analyze data. Results: The mean age in this group was 32.3±6.4 years (Mean±SD) and 28 (80%) patients were 20–40 y/O. This study showed that weakness, visual and paresthesia disturbance were the most common initial presentations with a prevalence of 80%, 34.2% and 57.1% respectively. This study indicated that relapsing-remitting MS was the most common clinical pattern with a prevalence of 54.2%. The mean level of prolactin in patients was 350.5±114.8 and in control group it was 160/7±57/6 (p<0.001). Conclusion: Serum prolactin level has significantly increased in definite Multiple Sclerosis patients. These findings suggest that an increase of serum prolactin can be a sensitive indicator for MS and prolactin antagonist agent administration is seriously considered to reduce the complications of MS in future. Experimental studies are recommended for thorough evaluation of antagonists efficacy.

Item Type: Article
Subjects: Medicine
Divisions: Feyz journal
Depositing User: ART . editor
Date Deposited: 13 May 2017 12:14
Last Modified: 03 Jun 2017 12:18
URI: http://eprints.kaums.ac.ir/id/eprint/2170

Actions (login required)

View Item View Item